---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-111706"
form_type: "8-K"
ticker: "DMII"
cik: "0002040475"
company_name: "Drugs Made In America Acquisition II Corp."
filed_at: "2025-11-18T23:59:59+00:00"
generated_at: "2026-05-16T18:56:49.524951+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Drugs Made In America Acquisition II Corp. appoints Saleem Elmasri as CFO after Glenn Worman resigns

## Summary
- Glenn Worman resigned as CFO and principal financial and accounting officer effective October 8, 2025, with no disagreement with the company.
- Saleem Elmasri was appointed CFO effective November 17, 2025, under a consulting agreement with Titan Advisory Services LLC.
- Compensation includes $42,000 per year ($3,500 per month) plus 100,000 ordinary shares transferred by CEO Lynn Stockwell.
- Elmasri is a CPA with 20 years experience, previously at PwC and as Managing Partner of Titan Advisory Services LLC since 2020.

## SEC filing metadata
- accession: 0001213900-25-111706
- form_type: 8-K
- ticker: DMII
- cik: 0002040475
- company_name: Drugs Made In America Acquisition II Corp.
- filed_at: 2025-11-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2040475/000121390025111706/0001213900-25-111706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2040475/000121390025111706/ea0265998-8k_drugs2.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-111706
- JSON: https://secwatch.observer/filing/0001213900-25-111706.json
- Plain text: https://secwatch.observer/filing/0001213900-25-111706.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.